» Articles » PMID: 12126625

Structural Basis of the Adaptive Molecular Recognition by MMP9

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2002 Jul 20
PMID 12126625
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Matrix metalloproteinase (MMPs) are critical for the degradation of extracellular matrix components and, therefore, need to be regulated tightly. Almost all MMPs share a homologous C-terminal haemopexin-like domain (PEX). Besides its role in macromolecular substrate processing, the PEX domains appear to play a major role in regulating MMP activation, localisation and inhibition. One intriguing property of MMP9 is its competence to bind different proteins, involved in these regulatory processes, with high affinity at an overlapping recognition site on its PEX domain. With the crystal structure of the PEX9 dimer, we present the first example of how PEX domains accomplish these diverse roles. Blade IV of PEX9 mediates the non-covalent and predominantly hydrophobic dimerisation contact. Large shifts of blade III and, in particular, blade IV, accompany the dimerisation, resulting in a remarkably asymmetric homodimeric structure. The asymmetry provides a novel mechanism of adaptive protein recognition, where different proteins (PEX9, PEX1, and TIMP1) can bind with high affinity to PEX9 at an overlapping site. Finally, the structure illustrates how the dimerisation generates new properties on both a physico-chemical and functional level.

Citing Articles

The Effect of Tissue Inhibitor of Metalloproteinases on Scar Formation after Spinal Cord Injury.

Mishra R, Nielsen B, Trudrung M, Lee S, Bolstad L, Hellenbrand D Cells. 2024; 13(18).

PMID: 39329731 PMC: 11430430. DOI: 10.3390/cells13181547.


Homeostatic Regulation of Pro-Angiogenic and Anti-Angiogenic Proteins via Hedgehog, Notch Grid, and Ephrin Signaling in Tibial Dyschondroplasia.

Nawaz S, Kulyar M, Mo Q, Yao W, Iqbal M, Li J Animals (Basel). 2023; 13(24).

PMID: 38136788 PMC: 10740744. DOI: 10.3390/ani13243750.


Network pharmacology reveals the potential of Dolastatin 16 as a diabetic wound healing agent.

Luthfiana D, Utomo D In Silico Pharmacol. 2023; 11(1):23.

PMID: 37719716 PMC: 10504231. DOI: 10.1007/s40203-023-00161-5.


MMP9: A Tough Target for Targeted Therapy for Cancer.

Augoff K, Hryniewicz-Jankowska A, Tabola R, Stach K Cancers (Basel). 2022; 14(7).

PMID: 35406619 PMC: 8998077. DOI: 10.3390/cancers14071847.


Structural characterisation of inhibitory and non-inhibitory MMP-9-TIMP-1 complexes and implications for regulatory mechanisms of MMP-9.

Charzewski L, Krzysko K, Lesyng B Sci Rep. 2021; 11(1):13376.

PMID: 34183752 PMC: 8238946. DOI: 10.1038/s41598-021-92881-x.